Abstract
Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the fundamental reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological processes. They represent a typical example of enzyme convergent evolution, as six genetically unrelated families of such enzymes were described so far. It is more than 70 years that synthetic compounds, mainly sulfonamides, have been used in clinical practice as diuretics and systemic acting antiglaucoma drugs. Recent studies using natural product libraries and isolated constituents from natural sources (such as fungi and plants) have disclosed novel chemotypes possessing carbonic anhydrase inhibition activities. These natural sources offer new opportunities in the search for new and more effective carbonic anhydrase inhibitors, and may serve as new leads for the design and development of future drugs.
This review will discuss the most recent advances in the search of naturally occurring products and their synthetic derivatives that inhibit the CAs and their mechanisms of action at molecular level. Plant extracts are not considered in the present review.
Keywords: Carbonic anhydrase inhibitors (CAIs), metalloenzymes, natural products, polyphenols, flavonoids.
Current Pharmaceutical Design
Title:An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Volume: 22 Issue: 12
Author(s): Anastasia Karioti, Fabrizio Carta and Claudiu T. Supuran
Affiliation:
Keywords: Carbonic anhydrase inhibitors (CAIs), metalloenzymes, natural products, polyphenols, flavonoids.
Abstract: Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the fundamental reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological processes. They represent a typical example of enzyme convergent evolution, as six genetically unrelated families of such enzymes were described so far. It is more than 70 years that synthetic compounds, mainly sulfonamides, have been used in clinical practice as diuretics and systemic acting antiglaucoma drugs. Recent studies using natural product libraries and isolated constituents from natural sources (such as fungi and plants) have disclosed novel chemotypes possessing carbonic anhydrase inhibition activities. These natural sources offer new opportunities in the search for new and more effective carbonic anhydrase inhibitors, and may serve as new leads for the design and development of future drugs.
This review will discuss the most recent advances in the search of naturally occurring products and their synthetic derivatives that inhibit the CAs and their mechanisms of action at molecular level. Plant extracts are not considered in the present review.
Export Options
About this article
Cite this article as:
Karioti Anastasia, Carta Fabrizio and Supuran T. Claudiu, An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity, Current Pharmaceutical Design 2016; 22 (12) . https://dx.doi.org/10.2174/1381612822666151211094235
DOI https://dx.doi.org/10.2174/1381612822666151211094235 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Applied Proteomics in Companion Animal Medicine
Current Proteomics MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells
Combinatorial Chemistry & High Throughput Screening Serum Tumor Markers in Stage I-II Breast Cancer
Medicinal Chemistry Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Emerging Protein Biomarkers in Epithelial Ovarian Cancer Prognosis: An Aid for Multivariate Indexing
Current Protein & Peptide Science Probing Gallic Acid for Its Broad Spectrum Applications
Mini-Reviews in Medicinal Chemistry The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines
Current Pharmaceutical Design Simultaneous Bilateral Secondary Pneumothorax Complicating Osteosarcoma: A Case Report
Current Respiratory Medicine Reviews Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Proteolytic Enzymes and Their Inhibition in Epithelial Ovarian Cancer
Current Enzyme Inhibition